{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'For patients receiving alemtuzumab, serum concentrations', 'and PK parameters will be studied.', 'Immune Markers (optional)', 'Immune Markers (optional): M0/D1 (baseline), M4, M12, M18', 'and M24/at EOTP.', 'STATISTICAL CONSIDERATIONS', 'Sample size determination:', 'At least 60 patients will be screened in this study to ensure', '50 evaluable patients to receive alemtuzumab treatment. This sample', 'size will provide at least 85% power to detect a 50% reduction in the', 'number of new or enlarging T2 lesions during continuation of prior DMT', '(Period 1) with their number in an equal period after the first course of', 'alemtuzumab (Period 2), assuming 10% dropout and a two-tailed', 'significance level of 0.05. These sample size calculations were', 'simulated using a correlated repeated measures negative binomial', 'regression model with generalized estimating equations (GEE) with', 'robust variance estimation to account for the within-patient correlation in', 'lesion counts between treatment Period 1 (prior DMT) and Period 2', '(alemtuzumab).', 'The sample size calculations also assume an overdispersion parameter', 'of 0.7 for both study periods, which is consistent with the variability', 'reported in other paediatric MS studies.', 'Analysis population:', 'Modified ITT (mITT): The primary analysis will be conducted on the', 'population of patients who have received at least 1 dose of', 'alemtuzumab and also have evaluable data for both Period 1 and', 'Period 2.', 'Safety: Safety and tolerability analyses will be conducted on all patients.', 'Primary analysis:', 'The number of new or enlarging T2 lesions during continuation of prior', 'DMT (Period 1) and in an equal length period after the first course of', 'alemtuzumab treatment (Period 2) will be analyzed and compared using', 'a repeated measures negative binomial regression model with GEE.', 'Analysis of secondary endpoints:', 'Safety and tolerability will be assessed using descriptive', 'statistics and evaluated in comparison to the adult data for the', 'treatment of MS using alemtuzumab.', 'EDSS (descriptive statistics, eg, percentages of', 'stable/improved/worsened since the end of Period 1).', 'The ARR at Year 2 will be estimated using a negative', 'binomial model with robust variance estimation.', 'The change from baseline in cognitive outcomes will be', 'analyzed descriptively.', 'Property of the Sanofi Group - strictly confidential', 'Page 10', 'VV-CLIN-02544065.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'The change from baseline in QoL measures will be analyzed', 'descriptively.', 'PK serum concentrations and PK parameters will be analyzed', 'descriptively.', 'PD parameters including lymphocyte subsets will be analyzed', 'descriptively.', 'Antialemtuzumab antibody results will be analyzed', 'descriptively.', 'The number and proportion of patients with new or enlarging', 'T2 lesions during Period 1 and Period 2 will be analyzed and', 'compared using a repeated measures logistic regression', 'model.', 'Planned Database lock date:', 'A partial database lock will be done after the last patient has completed', 'efficacy assessments including MRI at the end of Period 2. This', 'database lock will allow comparing lesion counts between Period 1', '(M-4 to M0) and Period 2 (M4-M8). No formal interim analysis will be', 'performed.', 'The second database lock will be after the last patient has completed', 'the safety monitoring phase (M60).', 'DURATION OF STUDY PERIOD (per', 'Approximately 5 years 5 months:', 'patient)', 'Screening period: maximum 28 days prior to M 4.', 'Prior DMT phase: approximately 4 months.', 'Alemtuzumab treatment phase: approximately 2 years.', 'Safety follow-up period: approximately 3 years.', 'STUDY COMMITTEES', 'Scientific Advisory Committee:', 'Yes', 'No', 'The Scientific Advisory Committee (SAC) is composed of field experts', 'and Sponsor-based scientists with clinical and methodological', 'expertise. This Committee, led by a Chairperson, is selected by the', 'Sponsor for advice regarding scientific issues and operational conduct', 'of the study. The SAC will also review any amendments, and provide', 'input regarding interpretation of study results.', 'Among its responsibilities, the SAC will receive study status reports', 'from the Sponsor, and will review the recommendations from the data', 'monitoring committee (DMC) throughout the study.', 'Moreover, the SAC will be responsible for the primary publication(s)', 'emanating from the study. The Principal Investigator (PI) of the study', 'will be selected by the Sponsor and will be the first author for the', 'primary publication(s). Pls at the 3 sites enrolling the most patients will', 'also be included as authors for the primary publication, in addition to the', 'SAC members.', 'Detailed activities and responsibilities of the SAC are provided in the', 'SAC charter.', 'Data Monitoring Committee:', 'Yes', 'No', 'A DMC, operating independently from the Sponsor and clinical', 'Investigators, will be responsible for overseeing the safety of patients', 'and the risk/benefit ratio throughout the study. This committee is', 'composed of externally-based individuals with expertise in the disease', 'under study, biostatistics and/or clinical research. The primary', 'Property of the Sanofi Group - strictly confidential', 'Page 11', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}